StocksMedium•4 November 2026•
1 min read
Revolution Medicines Beats Q3 Earnings Estimates Despite Widening Losses
Key Facts
1Revolution Medicines reported a quarterly loss of $1.9 per share, narrower than the Zacks Consensus Estimate of a $2.34 loss.
2The company's loss widened compared to a year ago when it reported a loss of $1.61 per share.
Revolution Medicines reported a quarterly loss of $1.9 per share for the third quarter of 2026, beating analyst expectations. According to Zacks, the result was narrower than the consensus estimate of a $2.34 loss per share, representing a bottom-line performance that exceeded market forecasts.
The company's loss widened compared to the same period last year, when it reported a loss of $1.61 per share. In the markets, RVMD closed at $194.23 on November 3, 2026, having reached a day high of $197 and a day low of $188.63.